GLP-1 (Glucagon-Like Peptide-1) is a natural hormone involved in controlling blood sugar levels. It stimulates the release of insulin only when blood sugar levels become too high. In people with type 2 diabetes, GLP-1 secretion is often impaired.
The pharmaceutical company Novo Nordisk is developing an analogue of this drug to be taken orally in the treatment of type 2 diabetes. Unfortunately, its release is likely still a few years away.